99 related articles for article (PubMed ID: 31744972)
1. A Novel Mutation in Neurodegeneration with Brain Iron Accumulation - A Case Report.
Nagarjunakonda S; Daggumati R; Uppala V; Gajula R; Amalakanti S
Neurol India; 2019; 67(5):1341-1343. PubMed ID: 31744972
[TBL] [Abstract][Full Text] [Related]
2. Neurodegeneration with brain iron accumulation.
Gregory A; Hayflick SJ
Folia Neuropathol; 2005; 43(4):286-96. PubMed ID: 16416393
[TBL] [Abstract][Full Text] [Related]
3. Case of Hallervorden-Spatz Syndrome: A Tale of Twin Sisters.
Reddy N; Sharma J; Sharma A
Neurol India; 2024 Mar; 72(2):411-413. PubMed ID: 38691487
[TBL] [Abstract][Full Text] [Related]
4. Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories.
Arber CE; Li A; Houlden H; Wray S
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):220-41. PubMed ID: 25870938
[TBL] [Abstract][Full Text] [Related]
5. Pallidal neuronal apolipoprotein E in pantothenate kinase-associated neurodegeneration recapitulates ischemic injury to the globus pallidus.
Woltjer RL; Reese LC; Richardson BE; Tran H; Green S; Pham T; Chalupsky M; Gabriel I; Light T; Sanford L; Jeong SY; Hamada J; Schwanemann LK; Rogers C; Gregory A; Hogarth P; Hayflick SJ
Mol Genet Metab; 2015 Dec; 116(4):289-97. PubMed ID: 26547561
[TBL] [Abstract][Full Text] [Related]
6. Patient and caregiver experiences with pantothenate kinase-associated neurodegeneration (PKAN): results from a patient community survey.
Klopstock T; Mercimek-Andrews S; Jurecka A; Wood P; Cwyl M; Klucken A; López A; Scalise R; Valle A; Mollet F; Perez-Duenas B; Skowronska M; Chroscinska-Krawczyk M; Escolar ML; Wade A; Rintell D
Orphanet J Rare Dis; 2023 Aug; 18(1):257. PubMed ID: 37653408
[TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration with brain iron accumulation: an overview.
Tonekaboni SH; Mollamohammadi M
Iran J Child Neurol; 2014; 8(4):1-8. PubMed ID: 25657764
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Pantothenate-Kinase Neurodegeneration With Baclofen, Botulinum Toxin, and Deferiprone: A Case Report.
Hameed M; Siddiqui F; Khan MK; Tadisetty S; Gangishetti PK
Brain Neurorehabil; 2023 Nov; 16(3):e25. PubMed ID: 38047104
[TBL] [Abstract][Full Text] [Related]
9. Clinical and imaging characteristics of late onset mitochondrial membrane protein-associated neurodegeneration (MPAN).
Gore E; Appleby BS; Cohen ML; DeBrosse SD; Leverenz JB; Miller BL; Siedlak SL; Zhu X; Lerner AJ
Neurocase; 2016 Oct; 22(5):476-483. PubMed ID: 27801611
[TBL] [Abstract][Full Text] [Related]
10. Olfactory status in neurodegeneration with brain iron accumulation disorders.
Amini E; Rohani M; Jalessi M; Azad Z; Valzania F; Cavallieri F; Farhadi M; Gholibeigian Z
Neurol Sci; 2024 Feb; 45(2):647-654. PubMed ID: 37651040
[TBL] [Abstract][Full Text] [Related]
11. Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders.
Amini E; Rohani M; Lang AE; Azad Z; Habibi SAH; Alavi A; Shahidi G; Emamikhah M; Chitsaz A
Mov Disord Clin Pract; 2024 Jan; 11(1):53-62. PubMed ID: 38291840
[TBL] [Abstract][Full Text] [Related]
12. Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA).
Schneider SA; Dusek P; Hardy J; Westenberger A; Jankovic J; Bhatia KP
Curr Neuropharmacol; 2013 Jan; 11(1):59-79. PubMed ID: 23814539
[TBL] [Abstract][Full Text] [Related]
13. Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12.
Landouré G; Zhu PP; Lourenço CM; Johnson JO; Toro C; Bricceno KV; Rinaldi C; Meilleur KG; Sangaré M; Diallo O; Pierson TM; Ishiura H; Tsuji S; Hein N; Fink JK; Stoll M; Nicholson G; Gonzalez MA; Speziani F; Dürr A; Stevanin G; Biesecker LG; ; Accardi J; Landis DM; Gahl WA; Traynor BJ; Marques W; Züchner S; Blackstone C; Fischbeck KH; Burnett BG
Hum Mutat; 2013 Oct; 34(10):1357-60. PubMed ID: 23857908
[TBL] [Abstract][Full Text] [Related]
14. Autosomal Dominant MPAN: Mosaicism Expands the Clinical Spectrum to Atypical Late-Onset Phenotypes.
Angelini C; Durand CM; Fergelot P; Deforges J; Vital A; Menegon P; Sarrazin E; Bellance R; Mathis S; Gonzalez V; Renaud M; Frismand S; Schmitt E; Rouanet M; Burglen L; Chabrol B; Desnous B; Arveiler B; Stevanin G; Coupry I; Goizet C
Mov Disord; 2023 Nov; 38(11):2103-2115. PubMed ID: 37605305
[TBL] [Abstract][Full Text] [Related]
15. The first reports of FA2H-associated neurodegeneration from two unrelated Iranian families.
Hashemi N; Abadi RNS; Alavi A; Rohani M; Ghasemi A; Tavasoli AR
Neurol Sci; 2023 Dec; 44(12):4359-4362. PubMed ID: 37410270
[TBL] [Abstract][Full Text] [Related]
16. Genetic Targets and Applications of Iron Chelators for Neurodegeneration with Brain Iron Accumulation.
Marupudi N; Xiong MP
ACS Bio Med Chem Au; 2024 Jun; 4(3):119-130. PubMed ID: 38911909
[TBL] [Abstract][Full Text] [Related]
17. Phenotype and natural history of mitochondrial membrane protein-associated neurodegeneration.
Iankova V; Sparber P; Rohani M; Dusek P; Büchner B; Karin I; Schneider SA; Gorriz JM; Kmiec T; Klopstock T
Brain; 2024 Apr; 147(4):1389-1398. PubMed ID: 37831662
[TBL] [Abstract][Full Text] [Related]
18. Ataxic gait and dysarthria in a child: pantothenate kinase-associated neurodegeneration as a diagnosis.
Naggar A; Laasri K; Fadil M; Allali N; El Haddad S; Chat L
Oxf Med Case Reports; 2023 Dec; 2023(12):omad134. PubMed ID: 38145266
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
